128 related articles for article (PubMed ID: 3178437)
1. [Pharmacokinetics of antilipemic agents. 4. Biotransformation of the antilipemic agent ciprofibrate (2-(4-(2,2-dichlorcyclopropyl)-phenoxy)-2-methylpropionic acid)].
Oelschläger H; Rothley D; Schmidt W
Arch Pharm (Weinheim); 1988 Jun; 321(6):367-70. PubMed ID: 3178437
[No Abstract] [Full Text] [Related]
2. [The pharmacokinetics of antilipemic agents. 5. Is 2-(4-hydroxyphenoxy)-2-methylpropionic acid a metabolite of the antilipemic ciprofibrate?].
Oelschläger H; Rothley D; Hellwich KH; Schmidt W
Arch Pharm (Weinheim); 1989 Jun; 322(6):337-42. PubMed ID: 2774869
[TBL] [Abstract][Full Text] [Related]
3. [The pharmacokinetics of hypolipemic agents. 6. Is 2-(4-(2,2-dichlorocyclopropyl)-phenoxy)-propane a metabolite of the hypolipemic ciprofibrate?].
Oelschläger H; Rothley D; Hellwich KH; Schmidt W
Arch Pharm (Weinheim); 1989 Oct; 322(10):629-32. PubMed ID: 2624522
[TBL] [Abstract][Full Text] [Related]
4. [The pharmacokinetics of hypolipemic agents. 10. The dehalogenation of the hypolipemic agent ciprofibrate].
Oelschläger H; Hellwich KH; Rothley D
Arch Pharm (Weinheim); 1994 Apr; 327(4):261-5. PubMed ID: 8204026
[TBL] [Abstract][Full Text] [Related]
5. [Conjugation reactions of ciprofibrate with human and laboratory animals].
Oelschläger H; Müller D; Hellwich KH; Ueberall S; Seeling A; Machts H; Hofmann B; Glöckner R
Arzneimittelforschung; 2003; 53(4):247-53. PubMed ID: 12785120
[TBL] [Abstract][Full Text] [Related]
6. The influence of renal insufficiency and haemodialysis on the kinetics of ciprofibrate.
Ferry N; Bernard N; Pozet N; Gardes E; Cuisinaud G; Labeeuw M; Zech PY; Sassard J
Br J Clin Pharmacol; 1989 Dec; 28(6):675-81. PubMed ID: 2611089
[TBL] [Abstract][Full Text] [Related]
7. The antilipemic effectiveness of aluminium clofibrate on hyperlipidemic patients with or without diabetes mellitus.
Lam HC; Li SH; Wang JT; Tang KT; Ho LT
Zhonghua Yi Xue Za Zhi (Taipei); 1987 Nov; 40(5):463-70. PubMed ID: 3332236
[No Abstract] [Full Text] [Related]
8. Determination of ciprofibrate in human plasma by high-performance liquid chromatography.
Park GB; Biddlecome CE; Koblantz C; Edelson J
J Chromatogr; 1982 Feb; 227(2):534-9. PubMed ID: 7061664
[No Abstract] [Full Text] [Related]
9. Metabolic effects of a new hypolipidemic agent, ciprofibrate.
Arnold A; McAuliff MP; Beyler AL
J Pharm Sci; 1979 Dec; 68(12):1557-8. PubMed ID: 529054
[TBL] [Abstract][Full Text] [Related]
10. The effect of ciprofibrate on gastric secretion in the rat.
Eason CT; Pattison A; Howells DD; Bonner FW
J Pharm Pharmacol; 1988 Jul; 40(7):512-3. PubMed ID: 2904995
[TBL] [Abstract][Full Text] [Related]
11. [Stability of antilipidemic etofibrate and its metabolites towards gastrointestinal and blood hydrolases (author's transl)].
Oelschläger H; Rothley D; Ewert M; Nachev P
Arzneimittelforschung; 1980; 30(6):984-8. PubMed ID: 7191278
[TBL] [Abstract][Full Text] [Related]
12. Comparative pharmacokinetics of 400 mg bezafibrate after a single oral administration of a new slow-release preparation and the currently available commercial form.
Ledermann H; Kaufmann B
J Int Med Res; 1981; 9(6):516-20. PubMed ID: 7319135
[TBL] [Abstract][Full Text] [Related]
13. Characterization of ciprofibrate and clofibric acid as peroxisomal proliferators in primary cultures of rat hepatocytes.
Feller DR; Singh Y; Shirhatti VR; Kocarek TA; Liu CT; Krishna G
Hepatology; 1987; 7(3):508-16. PubMed ID: 3570161
[TBL] [Abstract][Full Text] [Related]
14. Irreversible inhibition of hepatic glutathione S-transferase by ciprofibrate, a peroxisome proliferator.
Awasthi YC; Singh SV; Goel SK; Reddy JK
Biochem Biophys Res Commun; 1984 Sep; 123(3):1012-8. PubMed ID: 6487318
[TBL] [Abstract][Full Text] [Related]
15. Influence of a fibric acid type of hypolipidemic agent on the oxidative metabolism of arachidonic acid by liver microsomal cytochrome P-450.
Capdevila J; Kim YR; Martin-Wixtrom C; Falck JR; Manna S; Estabrook RW
Arch Biochem Biophys; 1985 Nov; 243(1):8-19. PubMed ID: 3933431
[TBL] [Abstract][Full Text] [Related]
16. Activation of hypolipidaemic drugs to acyl-coenzyme A thioesters.
Bronfman M; Amigo L; Morales MN
Biochem J; 1986 Nov; 239(3):781-4. PubMed ID: 3827829
[TBL] [Abstract][Full Text] [Related]
17. Steady-state kinetics of bezafibrate and clofibrate in healthy female volunteers.
Abshagen U; Spörl-Radun S; Marinow J
Eur J Clin Pharmacol; 1980 Apr; 17(4):305-8. PubMed ID: 6995131
[TBL] [Abstract][Full Text] [Related]
18. "In vitro" metabolism of bezafibrate by rat liver.
Maffei FR; Carini M; Bertuletti R; Tofanetti O
Pharmacol Res Commun; 1981 Feb; 13(2):121-32. PubMed ID: 7220572
[No Abstract] [Full Text] [Related]
19. Pharmacodynamic activity of lipoprotein lipase and hepatic lipase, and pharmacokinetic parameters measured in normolipidaemic subjects receiving ciprofibrate (100 or 200 mg/day) or micronised fenofibrate (200 mg/day) therapy for 23 days.
Desager JP; Horsmans Y; Vandenplas C; Harvengt C
Atherosclerosis; 1996 Jul; 124 Suppl():S65-73. PubMed ID: 8831918
[TBL] [Abstract][Full Text] [Related]
20. Disposition of etofibrate, clofibric and nicotinic acid esters, and their products in dogs.
Garrett ER; Altmayer P
J Pharm Sci; 1985 Mar; 74(3):295-9. PubMed ID: 4009437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
